NCT06495229View on ClinicalTrials.gov

Study of CM310 in Adolescent Subjects With Atopic Dermatis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

CM310

Interleukin-4 receptor(IL-4Rα) monoclonal antibody

Trial Locations (1)

Unknown

Peking University People's hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT06495229 - Study of CM310 in Adolescent Subjects With Atopic Dermatis | Biotech Hunter | Biotech Hunter